Platinum-Pemetrexed Chemotherapy for Recurrent Ovarian Cancer (ROC): A Single Center Experience
| Autor: | George John, Raju Titus Chacko, Ashish Singh, Bijesh Yadav, Vinotha Thomas, Anuradha Chandramohan, Ajoy Oommen John, Anjana Joel, Ajit Sebastian, Sherin Daniel, Jeba Karunya Ramireddy, Josh Thomas Georgy |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Cancer Research
medicine.medical_specialty Anemia medicine.medical_treatment Pemetrexed Neutropenia Single Center Gastroenterology Carboplatin chemistry.chemical_compound Maintenance therapy Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Retrospective Studies Ovarian Neoplasms Chemotherapy business.industry General Medicine Middle Aged medicine.disease Bevacizumab Serous fluid Oncology chemistry Female Neoplasm Recurrence Local business medicine.drug |
| Zdroj: | Cancer investigation. 39(10) |
| ISSN: | 1532-4192 |
| Popis: | In this retrospective analysis of 36 patients with recurrent ovarian cancer (ROC) treated with platinum pemetrexed doublet ± bevacizumab, the median age was 54.5 years (47-60) and 33 (91.7%) had serous histology. The overall response rate [ORR = complete (CR)+partial (PR) response] was 83.3%. At a median follow-up of 16 months, the median PFS was 13.8 months (95% CI: 10.849-20.580) and median OS 30.6 months, (95% CI: 21.46 months-NR). The incidence of Grade 3/4 anemia, thrombocytopenia, neutropenia and non-hematological toxicity was 19.4%, 3.9%, 16.6%, and 8.3%. Platinum pemetrexed chemotherapy in ROC is safe and effective treatment option. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|